A cell-based screening system for anti-influenza A virus agents

Wan Ying Wong, Sheng Wei Loh, Wei Lun Ng, Ming Cheang Tan, Kok Siong Yeo, Chung Yeng Looi, Mohd Jamil Maah, Chee Kwee Ea

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Emerging of drug resistant influenza A virus (IAV) has been a big challenge for anti-IAV therapy. In this study, we describe a relatively easy and safe cell-based screening system for anti-IAV replication inhibitors using a non-replicative strain of IAV. A nickel (II) complex of polyhydroxybenzaldehyde N4-thiosemicarbazone (NiPT5) was recently found to exhibit anti-inflammatory activity in vivo and in vitro. NiPT5 impedes the signaling cascades that lead to the activation of NF-κB in response to different stimuli, such as LPS and TNFα. Using our cell-based screening system, we report that pretreating cells with NiPT5 protects cells from influenza A virus (IAV) and vesicular stomatitis virus (VSV) infection. Furthermore, NiPT5 inhibits replication of IAV by inhibiting transcription and translation of vRNAs of IAV. Additionally, NiPT5 reduces IAV-induced type I interferon response and cytokines production. Moreover, NiPT5 prevents activation of NF-κB, and IRF3 in response to IAV infection. These results demonstrate that NiPT5 is a potent antiviral agent that inhibits the early phase of IAV replication.

Original languageEnglish (US)
Article number8672
JournalScientific Reports
Volume5
DOIs
StatePublished - Jan 1 2015

Fingerprint

Influenza A virus
Virus Diseases
Virus Replication
Thiosemicarbazones
Interferon Type I
Vesicular Stomatitis
Nickel
Antiviral Agents
Anti-Inflammatory Agents
Cytokines

ASJC Scopus subject areas

  • General

Cite this

Wong, W. Y., Loh, S. W., Ng, W. L., Tan, M. C., Yeo, K. S., Looi, C. Y., ... Ea, C. K. (2015). A cell-based screening system for anti-influenza A virus agents. Scientific Reports, 5, [8672]. https://doi.org/10.1038/srep08672

A cell-based screening system for anti-influenza A virus agents. / Wong, Wan Ying; Loh, Sheng Wei; Ng, Wei Lun; Tan, Ming Cheang; Yeo, Kok Siong; Looi, Chung Yeng; Maah, Mohd Jamil; Ea, Chee Kwee.

In: Scientific Reports, Vol. 5, 8672, 01.01.2015.

Research output: Contribution to journalArticle

Wong, WY, Loh, SW, Ng, WL, Tan, MC, Yeo, KS, Looi, CY, Maah, MJ & Ea, CK 2015, 'A cell-based screening system for anti-influenza A virus agents', Scientific Reports, vol. 5, 8672. https://doi.org/10.1038/srep08672
Wong WY, Loh SW, Ng WL, Tan MC, Yeo KS, Looi CY et al. A cell-based screening system for anti-influenza A virus agents. Scientific Reports. 2015 Jan 1;5. 8672. https://doi.org/10.1038/srep08672
Wong, Wan Ying ; Loh, Sheng Wei ; Ng, Wei Lun ; Tan, Ming Cheang ; Yeo, Kok Siong ; Looi, Chung Yeng ; Maah, Mohd Jamil ; Ea, Chee Kwee. / A cell-based screening system for anti-influenza A virus agents. In: Scientific Reports. 2015 ; Vol. 5.
@article{cbbd859e8aa74c12affddb0e5064a708,
title = "A cell-based screening system for anti-influenza A virus agents",
abstract = "Emerging of drug resistant influenza A virus (IAV) has been a big challenge for anti-IAV therapy. In this study, we describe a relatively easy and safe cell-based screening system for anti-IAV replication inhibitors using a non-replicative strain of IAV. A nickel (II) complex of polyhydroxybenzaldehyde N4-thiosemicarbazone (NiPT5) was recently found to exhibit anti-inflammatory activity in vivo and in vitro. NiPT5 impedes the signaling cascades that lead to the activation of NF-κB in response to different stimuli, such as LPS and TNFα. Using our cell-based screening system, we report that pretreating cells with NiPT5 protects cells from influenza A virus (IAV) and vesicular stomatitis virus (VSV) infection. Furthermore, NiPT5 inhibits replication of IAV by inhibiting transcription and translation of vRNAs of IAV. Additionally, NiPT5 reduces IAV-induced type I interferon response and cytokines production. Moreover, NiPT5 prevents activation of NF-κB, and IRF3 in response to IAV infection. These results demonstrate that NiPT5 is a potent antiviral agent that inhibits the early phase of IAV replication.",
author = "Wong, {Wan Ying} and Loh, {Sheng Wei} and Ng, {Wei Lun} and Tan, {Ming Cheang} and Yeo, {Kok Siong} and Looi, {Chung Yeng} and Maah, {Mohd Jamil} and Ea, {Chee Kwee}",
year = "2015",
month = "1",
day = "1",
doi = "10.1038/srep08672",
language = "English (US)",
volume = "5",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - A cell-based screening system for anti-influenza A virus agents

AU - Wong, Wan Ying

AU - Loh, Sheng Wei

AU - Ng, Wei Lun

AU - Tan, Ming Cheang

AU - Yeo, Kok Siong

AU - Looi, Chung Yeng

AU - Maah, Mohd Jamil

AU - Ea, Chee Kwee

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Emerging of drug resistant influenza A virus (IAV) has been a big challenge for anti-IAV therapy. In this study, we describe a relatively easy and safe cell-based screening system for anti-IAV replication inhibitors using a non-replicative strain of IAV. A nickel (II) complex of polyhydroxybenzaldehyde N4-thiosemicarbazone (NiPT5) was recently found to exhibit anti-inflammatory activity in vivo and in vitro. NiPT5 impedes the signaling cascades that lead to the activation of NF-κB in response to different stimuli, such as LPS and TNFα. Using our cell-based screening system, we report that pretreating cells with NiPT5 protects cells from influenza A virus (IAV) and vesicular stomatitis virus (VSV) infection. Furthermore, NiPT5 inhibits replication of IAV by inhibiting transcription and translation of vRNAs of IAV. Additionally, NiPT5 reduces IAV-induced type I interferon response and cytokines production. Moreover, NiPT5 prevents activation of NF-κB, and IRF3 in response to IAV infection. These results demonstrate that NiPT5 is a potent antiviral agent that inhibits the early phase of IAV replication.

AB - Emerging of drug resistant influenza A virus (IAV) has been a big challenge for anti-IAV therapy. In this study, we describe a relatively easy and safe cell-based screening system for anti-IAV replication inhibitors using a non-replicative strain of IAV. A nickel (II) complex of polyhydroxybenzaldehyde N4-thiosemicarbazone (NiPT5) was recently found to exhibit anti-inflammatory activity in vivo and in vitro. NiPT5 impedes the signaling cascades that lead to the activation of NF-κB in response to different stimuli, such as LPS and TNFα. Using our cell-based screening system, we report that pretreating cells with NiPT5 protects cells from influenza A virus (IAV) and vesicular stomatitis virus (VSV) infection. Furthermore, NiPT5 inhibits replication of IAV by inhibiting transcription and translation of vRNAs of IAV. Additionally, NiPT5 reduces IAV-induced type I interferon response and cytokines production. Moreover, NiPT5 prevents activation of NF-κB, and IRF3 in response to IAV infection. These results demonstrate that NiPT5 is a potent antiviral agent that inhibits the early phase of IAV replication.

UR - http://www.scopus.com/inward/record.url?scp=84923869804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923869804&partnerID=8YFLogxK

U2 - 10.1038/srep08672

DO - 10.1038/srep08672

M3 - Article

VL - 5

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 8672

ER -